Research programme: astaxanthin prodrugs - Cardax Pharmaceuticals

Drug Profile

Research programme: astaxanthin prodrugs - Cardax Pharmaceuticals

Alternative Names: CDX-085; Heptax; XanCor

Latest Information Update: 19 Nov 2015

Price : $50

At a glance

  • Originator Cardax Pharmaceuticals
  • Class Anti-inflammatories; Antineoplastics; Xanthophylls
  • Mechanism of Action Antioxidants; Oxygen radical scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hypertriglyceridaemia; Liver disorders; Metabolic syndrome; Rheumatoid arthritis; Thrombosis

Most Recent Events

  • 17 Nov 2015 Cardax Pharmaceuticals has patent protection for astaxanthin prodrugs in USA
  • 18 Jun 2015 Research programme: astaxanthin prodrugs is still in active development
  • 20 Jul 2009 Preclinical trials in Liver disorders in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top